WuXi Biologics (Cayman) Inc. (HKG:2269)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
25.75
+2.35 (10.04%)
May 29, 2025, 4:08 PM HKT
119.34%
Market Cap 104.77B
Revenue (ttm) 19.87B
Net Income (ttm) 3.57B
Shares Out 4.07B
EPS (ttm) 0.83
PE Ratio 30.84
Forward PE 21.73
Dividend n/a
Ex-Dividend Date n/a
Volume 104,572,637
Average Volume 37,253,842
Open 23.60
Previous Close 23.40
Day's Range 23.60 - 25.90
52-Week Range 10.14 - 29.15
Beta 0.56
RSI 61.28
Earnings Date Mar 21, 2025

About WuXi Biologics

WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufact... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 12,575
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2269
Full Company Profile

Financial Performance

In 2024, WuXi Biologics's revenue was 18.68 billion, an increase of 9.63% compared to the previous year's 17.03 billion. Earnings were 3.36 billion, a decrease of -1.28%.

Financial numbers in CNY Financial Statements

News

Hong Kong stocks jump as US blocks Trump’s tariffs in win for global trade

Hong Kong stocks jumped after a US court blocked President Donald Trump’s sweeping “reciprocal tariffs”, fuelling bets global trade tensions will ease. The Hang Seng Index rose 0.6 per cent to 23,385....

22 hours ago - South China Morning Post

WuXi Biologics Congratulates Partner CANbridge Pharmaceuticals on the Approval of Innovative Velaglucerase-beta for Injection (Gaurunning) for Gaucher Disease by China NMPA

Enabled by WuXi Biologics' industry-leading integrated technology platform, velaglucerase-beta for injection has successfully advanced from concept to commercialization. Velaglucerase-beta for injecti...

12 days ago - PRNewsWire

Driving Impact Through Responsibility: WuXi Biologics Releases 2024 Sustainability Report

Contributing to United Nations Sustainable Development Goals Enhancing transparency and effectiveness for corporate governance Empowering employees and delivering positive impact to communities Accele...

4 weeks ago - PRNewsWire

WuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive Year

Firm commitment to tackling climate change in support of United Nations Sustainable Development Goals Earth Day 2025 - Our Power, Our Planet, Contribute to a sustainable future SHANGHAI , April 22, 20...

5 weeks ago - PRNewsWire

WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou ...

WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site | WXXWY Stock News

5 weeks ago - GuruFocus

WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site

-          The campaign marks the successful commercial-scale PPQ completion of Asia's first 3 X 5,000L single-use bioreactors-          Proprietary process innovation reduces protein cost by nearly 7...

5 weeks ago - PRNewsWire

WuXi Biologics Wins Five Asia-Pacific Biopharma Excellence Awards

SHANGHAI , April 14, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received ...

6 weeks ago - PRNewsWire

Wuxi Biologics ADR reports FY results

2 months ago - Seeking Alpha

WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025

Revenue grew 9.6% YoY to RMB 18,675.4 million, with non-COVID revenue up 13.1% YoY Adjusted EBITDA grew 14.4% YoY to RMB7,999.3 million and Adjusted Net Profit increased 9.0% YoY to RMB5,396.9 million...

2 months ago - PRNewsWire

WuXi Biologics Celebrates Eighth Consecutive CDMO Leadership Award Win

WuXi Biologics Celebrates Eighth Consecutive CDMO Leadership Award Win

2 months ago - GuruFocus

WuXi Biologics Receives CDMO Leadership Awards for Eighth Consecutive Year

SHANGHAI , March 23, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received ...

2 months ago - PRNewsWire

WuXi Biologics Named to CDP Water Security "A List" for Second Consecutive Year

Launching the Water Excellence Stewardship (WES) program to advance UN Sustainable Development Goal 6 (SDG6) Contributing to the 2025 World Water Day campaign to ensure the availability of water and s...

2 months ago - PRNewsWire

WuXi Biologics Included in S&P Global Sustainability Yearbook 2025

Ranking in top 1% of S&P Global CSA Score Inclusion in Global Yearbook for third consecutive year Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI , March 10, 2025 /PRNewswire...

2 months ago - PRNewsWire

WuXi Biologics Launches EffiX™ Platform to Enhance Protein and DNA Production

WuXi Biologics Launches EffiX™ Platform to Enhance Protein and DNA Production

3 months ago - GuruFocus

WuXi Biologics Launches EffiX™ Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production

-          EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system.

3 months ago - PRNewsWire

WuXi Biologics Successfully Passes Japan PMDA GMP Inspection

WuXi Biologics Successfully Passes Japan PMDA GMP Inspection

3 months ago - GuruFocus

WuXi Biologics Again Passed GMP Inspection by Japan PMDA

WUXI, China , Feb. 26, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has ...

3 months ago - PRNewsWire

WuXi Biologics Awarded Platinum Medal by EcoVadis Sustainability Rating for Second Consecutive Year

Ranked among the top 1% of more than 150,000 companies across 185 countries Trusted by global partners for strong sustainability commitment Recognized as a leader in Green CRDMO, driving innovation fo...

3 months ago - PRNewsWire

WuXi Biologics Recognized as ESG Top-Rated Company by Morningstar Sustainalytics

WuXi Biologics Recognized as ESG Top-Rated Company by Morningstar Sustainalytics

3 months ago - GuruFocus

WuXi Biologics Recognized as Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics for Fifth Consecutive Year

Ranked among the top 1% of companies assessed in the pharmaceutical industry Recognized as a leader in Green CRDMO, driving innovation for a healthier future Committed to creating long-term value for ...

3 months ago - PRNewsWire

WuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 Million

WuXi Biologics' move to sell the facility could strengthen the company's cash flow and margins as it navigates global uncertainties.

5 months ago - WSJ

WuXi Bio to Sell Vaccine Facility to Merck for $500 Million

WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese company seeks to enhance its margins while continuing to navigate geopolitical t...

5 months ago - BNN Bloomberg